<DOC>
	<DOCNO>NCT00968331</DOCNO>
	<brief_summary>Oral Lenalidomide initiate day 1 cycle 1 dose 20 mg daily 21 day 7 day rest ( 28 day cycle ) total 4 cycle . Rituximab administer day 1 day 21 cycle dose 375 mg/m2 total 4 cycle . After induction phase , CR , PR SD continue Lenalidomide schedule 8 month .</brief_summary>
	<brief_title>Study Lenalidomide ( Revlimid ) Plus Rituximab ( Revlirit Regimen ) Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Understand voluntarily sign informed consent form . Be = 65 year age time sign informed consent form . Able adhere study visit schedule protocol requirement . Patients histological confirmation DLBCL . Stage disease study entry may include stage IIIIIIV accord Ann Arbor Classification Patients must fail least one prior treatment ECOG performance status equal le 2 study entry nLaboratory test result within range : Absolute neutrophil count equal major 1.0 x 109/L Platelet count equal major 50 x 109/L Serum creatinine equal le 2.0 mg/dL Total bilirubin equal less 1.5 mg/dL AST ( SGOT ) ALT ( SGPT ) equal less 2 x ULN equal less 5 x ULN hepatic metastasis present Hemoglobin equal major 8 g/dl Females childbearing potential ( FCBP ) must agree use two reliable form contraception simultaneously practice complete abstinence heterosexual intercourse follow time period relate study : 1. least 28days start study drug 2. participate study 3. least 28 day discontinuation study . The two method reliable contraception must include one highly effective method ( i.e . intrauterine device ( IUD ) , hormonal [ birth control pill , injection , implant ] , tubal ligation , partner 's vasectomy ) one additional effective ( barrier ) method ( i.e . latex condom , diaphragm , cervical cap ) . FCBP must refer qualified provider contraceptive method need . Disease free prior malignancy equal major 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation . ( patient intolerant ASA may use warfarin low molecular weight heparin ) . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 28 day baseline . Known hypersensitivity thalidomide . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Any prior use lenalidomide . Concurrent use anticancer agent treatment . Known positive HIV infectious hepatitis , type A , B C .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>relapsed refractory DLBCL</keyword>
</DOC>